Biocartis’ Post

Test for EGFR, ALK, ROS1, RET and METex14 in ONLY 3 HOURS and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers*. IDYLLA™ FIRST. Guiding First-Line Therapy Decisions in NSCLC ⏱️ Learn more 👉🏻 https://lnkd.in/enNpBhir #Biocartis #Idylla #EGFR #GeneFusion #ALK #ROS1 #RET #METex14 #LungCancer #NSCLC *Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(4), 339–357.

Test for EGFR, ALK, ROS1, RET and METex14 in ONLY 3 HOURS and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers*. IDYLLA™ FIRST. Guiding First-Line Therapy Decisions in NSCLC ⏱️ Learn more 👉🏻 https://lnkd.in/enNpBhir #Biocartis #Idylla #EGFR #GeneFusion #ALK #ROS1 #RET #METex14 #LungCancer #NSCLC *Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(4), 339–357.

Revolutionize your NSCLC diagnostics with Idylla™ 🏆 ⏱️Speed up your therapy decisions for better patient outcomes! Test for EGFR, ALK, ROS1, RET, METex14 in only 3 hours and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers* 👉 Read more https://lnkd.in/e-qHZv8T Your patients, our priority. Guiding them to the right therapy within hours ⚡ #Idylla #Biocartis #GeneFusion #ALK #ROS1 #RET #METex14 #EGFR #LungCancer #NSCLC *Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(4), 339–357.

Revolutionize your NSCLC diagnostics with Idylla™ 🏆 ⏱️Speed up your therapy decisions for better patient outcomes! Test for EGFR, ALK, ROS1, RET, METex14 in only 3 hours and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers* 👉 Read more https://lnkd.in/e-qHZv8T Your patients, our priority. Guiding them to the right therapy within hours ⚡ #Idylla #Biocartis #GeneFusion #ALK #ROS1 #RET #METex14 #EGFR #LungCancer #NSCLC *Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(4), 339–357.

Revolutionize your NSCLC diagnostics with Idylla™ 🏆 ⏱️Speed up your therapy decisions for better patient outcomes! Test for EGFR, ALK, ROS1, RET, METex14 in only 3 hours and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers* 👉 Read more https://lnkd.in/e-qHZv8T Your patients, our priority. Guiding them to the right therapy within hours ⚡ #Idylla #Biocartis #GeneFusion #ALK #ROS1 #RET #METex14 #EGFR #LungCancer #NSCLC *Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(4), 339–357.

The Oncology Brothers and Paolo Tarantino, MD, discuss ongoing studies investigating novel uses of oral SERDs, highlighting trials exploring its combination with other therapies and its potential in different patient populations. #bcsm https://lnkd.in/etAdubcs

Merck Group & Kelun LifeSciences (Pvt)Ltd’s TROP-2 ADC could be a ray of hope post Phase III data readout highlighting its efficacy in the most aggressive breast cancer type, TNBC. Sacituzumab tirumotecan, known as SKB264, has demonstrated outstanding potential in the treatment of advanced triple-negative breast cancer (TNBC), substantially lowering the risk of disease progression or mortality while maintaining an acceptable safety profile. An interim analysis conducted on June 21, 2023, indicated that patients treated with SKB264 experienced a median progression-free survival (PFS) of 5.7 months, which is more than twice the 2.3 months observed in patients who received standard chemotherapy. The 6-month PFS rates further highlighted the difference, with SKB264 achieving a rate of 43.4% compared to 11.1% for chemotherapy. In patients exhibiting high TROP2 expression, the median PFS for SKB264 was 5.8 months, significantly longer than the 1.9 months for those on chemotherapy. DelveInsight Business Research LLP's American Society of Clinical Oncology (ASCO) 2024 Exclusive Coverage, Unlock the Best Expert Insights and Comprehensive Analysis @ https://lnkd.in/dmRMbVCf #ASCO24 #ASCO #ASCOconference #SacituzumabTirumotecan #SKB264 #AdvancedTNBCTreatment #CancerTherapyInnovation #ProgressionFreeSurvival #TROP2Expression #BreastCancerTreatment #OncologyBreakthroughs #ChemotherapyAlternatives #CancerSurvivalImprovements #TargetedCancerTherapy #TripleNegativeBreastCancer #CancerResponseRate #MedicalResearchAdvances  #HopeForCancerPatients #PersonalizedOncology #CancerTreatmentOptions

Continuing our quick look at published trials for novel therapy alternatives to radical cystectomy for BCG-unresponsive non-muscle-invasive bladder cancer.   4. Intravesical portuzumab monatox-qqrs (Vicinium)   Vicinium is a recombinant fusion protein that blocks protein synthesis in order to mediate tumour cell death. The FDA denied approval for its use in BCG-unresponsive non-muscle-invasive bladder cancer following a review of the results of a phase 3 single-arm clinical trial. The 3-month complete response rate was 40%, and 52% of patients who responded remained disease-free for 12 months after treatment.   Tomorrow: IL-15 superagonist + BCG   #medicalinnovation #bladdercancer #HIVEC #CombatMedical 

Continuing our quick look at published trials for novel therapy alternatives to radical cystectomy for BCG-unresponsive non-muscle-invasive bladder cancer.   4. Intravesical portuzumab monatox-qqrs (Vicinium)   Vicinium is a recombinant fusion protein that blocks protein synthesis in order to mediate tumour cell death. The FDA denied approval for its use in BCG-unresponsive non-muscle-invasive bladder cancer following a review of the results of a phase 3 single-arm clinical trial. The 3-month complete response rate was 40%, and 52% of patients who responded remained disease-free for 12 months after treatment.   Tomorrow: IL-15 superagonist + BCG   #medicalinnovation #bladdercancer #HIVEC #CombatMedical 

According to the American Cancer Society, out of the total lung cancer cases, approximately 80─85% of lung cancers are NSCLC. SKB264, a third-generation ADC, in combination with KL-A167, has exhibited promising efficacy in Phase II studies for treatment-naive advanced NSCLC patients. The therapy demonstrated high response rates, favorable disease control, and a manageable safety profile. Get Ahead with Expert Insights and Full Analysis through DelveInsight Business Research LLP's Exclusive ASCO 2024 Coverage! https://lnkd.in/gwXQzR_f #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders